ACRIPTEGA

Brand name authorized in: South Africa

Active ingredients

The drug ACRIPTEGA contains a combination of these active pharmaceutical ingredients (APIs):

1 Dolutegravir
UNII 1Q1V9V5WYQ - DOLUTEGRAVIR SODIUM

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.

Read about Dolutegravir
2 Lamivudine
UNII 2T8Q726O95 - LAMIVUDINE

Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription.

Read about Lamivudine
3 Tenofovir disoproxil
UNII OTT9J7900I - TENOFOVIR DISOPROXIL FUMARATE

Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination.

Read about Tenofovir disoproxil

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Lamivudine, tenofovir disoproxil and dolutegravir
J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR27